Vetera GoldXP (Canada)

Company: Boehringer

Encephalomyelitis-Rhinopneumonitis-Influenza-West Nile Virus Vaccine

Eastern & Western, Killed Virus

Tetanus Toxoid

Veterinary Use Only.

Vetera GoldXP Indications

For vaccination of healthy horses 4 months of age or older, including pregnant mares, as an aid in the prevention of disease caused by Eastern and Western Encephalomyelitis, and tetanus; as an aid in the prevention of viremia and mortality, and an aid in the reduction of severity of clinical disease caused by West Nile Virus; as an aid in the reduction of respiratory disease caused by Equine Herpesvirus types 1 and 4 (EHV-1 and EHV-4); and as an aid in the reduction of respiratory disease and shedding caused by A2 Equine Influenza virus. Product contains Kentucky Lineage (KY/95), Florida sublineage clade 1 (OH/03), and Florida sublineage clade 2 (RI/07) equine influenza strains. Efficacy (DOI) has been demonstrated for at least 6 months against OH/03. The duration of immunity against West Nile Virus is at least 12 months.

Administration and dosage: Shake well before use. Using aseptic technique, vaccinate horses intramuscularly with a 1 mL dose. Administer a second 1 mL dose intramuscularly in 3-4 weeks using a different injection site. Revaccinate annually and prior to anticipated exposure with a single 1 mL intramuscular dose.

Precautions

Store at 2-7°C. Do not freeze. Do not vaccinate within 21 days before slaughter. Use entire contents when first opened. Anaphylactoid reactions may occur following use. Antidote: Epinephrine. Preservatives: Gentamicin and Amphotericin B.

Vetera^® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH. Used under license.

Manufactured by: Boehringer Ingelheim Vetmedica, Inc., St. Joseph, Missouri 64506 U.S.A.

US Vet. Lic. No. 124

Manufactured for: Boehringer Ingelheim (Canada) Ltd., Burlington, Ontario L7L 5H4

CPN: 1230141.2